Adding immunotherapy around gastric cancer surgery improved pooled survival
Pooled randomized trials favored adding checkpoint inhibitors to chemotherapy, but safety and subgroup findings need cautious interpretation.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Adding checkpoint inhibitors to chemotherapy around surgery improved pooled survival outcomes in operable stomach or gastroesophageal junction cancer. Grade ≥3 treatment-related side effects showed no statistically clear increase, which does not establish equal safety. These findings apply to this specific treatment setting and do not determine an individual's treatment choice.
The abstract omits follow-up lengths and absolute survival differences. This abstract-based account cannot assess variation across drugs or chemotherapy regimens.
What researchers found
Overall survival: hazard ratio
Combination versus chemotherapy alone around surgery. Hazard describes the death rate over time; the lower relative rate favors the combination. The interval gives plausible ratios, not absolute survival gains. Follow-up length unreported.
Response and survival were separate outcomes
The review assessed both cancer response in surgical tissue and survival. Pooled results favored the combination on both types of outcome; survival benefits were not inferred solely from tissue response.
Subgroup significance has limits
Results were statistically significant for PD-L1-positive tumors but not for PD-L1-negative tumors. This does not establish a difference between subgroups or show that benefit is absent in the latter group.
The original publication
Perioperative chemoimmunotherapy for patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
Omori R, Fujiwara Y, Tokunaga K et al.
JNCI Cancer Spectr · 2026
- PubMed ID
- 41581222
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.